| 查看: 1327 | 回复: 26 | |||
| 【奖励】 本帖被评价20次，作者york6999增加金币 16 个 | |||
[资源]
Phosphodiesterases and Their Inhibitors
|
|||
|
Phosphodiesterases and Their Inhibitors Spiros Liras, Andrew S. Bell, Raimund Mannhold, Hugo Kubinyi, Gerd Folkers Wiley 2014 ISBN: 3527332197 Table of Contents List of Contributors XI Preface XV A Personal Foreword XVII 1 Introduction 1 Andrew S. Bell and Spiros Liras 2 Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry 9 Dafydd R. Owen 2.1 Introduction 9 2.2 The First-Generation Agents 10 2.3 PDE5 as a Mechanism and Alternative Indications Beyond MED 11 2.4 A Summary of PDE5 Chemotypes Reported Post-2010 11 2.5 Second-Generation PDE5 Inhibitors from Pfizer: Pyrazolopyrimidines 12 2.6 Second-Generation PDE5 Inhibitors from Pfizer: Pyridopyrazinones 18 2.7 Conclusions 25 References 25 3 PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors 29 Jayvardhan Pandit 3.1 Introduction 29 3.2 Isoforms, Domain Organization, and Splice Variants 30 3.3 Structural Features of the Catalytic Site 31 3.4 Regulation of PDE4 Activity 32 3.5 Crystal Structure of Regulatory Domains of PDE4 33 3.6 UCR2 Interaction and Selectivity 38 3.7 Conclusions 39 References 40 4 PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects 45 Etzer Darout, Elnaz Menhaji-Klotz, and Thomas A. Chappie 4.1 Introduction 45 4.2 Brief Summary of pan-PDE4 Inhibitors 46 4.2.1 Rolipram 47 4.2.2 Roflumilast 48 4.2.3 Cilomilast 48 4.2.4 Apremilast 49 4.3 PDE4 Strategies to Avoid Gastrointestinal Events 49 4.3.1 Allosteric Modulation 49 4.3.2 PDE4D Selectivity 53 4.3.3 Pfizer 53 4.3.4 Novartis 54 4.3.5 Merck-Frosst 54 4.3.6 GEBR-7b 55 4.3.7 PDE4B Selectivity 55 4.3.8 Asahi Kasei 56 4.3.9 GlaxoSmithKline 56 4.3.10 Pfizer 57 4.3.11 Tissue Targeting 57 4.3.12 Polypharmacology 58 4.3.13 Olanzapine Derivatives 58 4.4 Conclusions 59 References 60 5 The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A 65 Thomas A. Chappie and Patrick Verhoest 5.1 Enzymology and Protein Structure 66 5.2 Papaverine-Related PDE10A Inhibitors 69 5.3 MP-10/PF-2545920 Class of Inhibitors 72 5.4 PF-2545920/MP-Inspired Inhibitors 74 5.5 PF-2545920/Papaverine/Quinazoline Hybrid Series of Inhibitors 75 5.6 PET Ligand Development 77 5.7 Summary and Future 79 References 79 6 The State of the Art in Selective PDE2A Inhibitor Design 83 Christopher W. am Ende, Bethany L. Kormos, and John M. Humphrey 6.1 Introduction 83 6.2 Selective PDE2A Inhibitors 84 6.2.1 Bayer 84 6.2.2 Altana AG 85 6.2.3 Biotie Therapies 87 6.2.4 Boehringer Ingelheim 88 6.2.5 Janssen 89 6.2.6 Lundbeck 92 6.2.7 Merck 93 6.2.8 Neuro3d 95 6.2.9 Pfizer 95 6.3 Methods 100 6.4 Conclusions 100 References 101 7 Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery 105 Hengming Ke, Yousheng Wang, Yiqian Wan, and Hai-Bin Luo 7.1 Introduction 105 7.2 Subtle Asymmetry of the PDE9 Dimer in the Crystals 105 7.3 The Structure of the PDE9 Catalytic Domain 107 7.4 Interaction of Inhibitors with PDE9 108 7.5 Implication on Inhibitor Selectivity 110 References 114 8 PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases 117 Michelle M. Claffey, Christopher J. Helal, and Xinjun Hou 8.1 PDE9A Enzymology and Pharmacology 117 8.2 Crystal Structures of PDE9A Inhibitors 119 8.3 Medicinal Chemistry Efforts toward Identifying PDE9A Inhibitors for Treating Cognitive Disorders 120 8.3.1 Bayer 120 8.3.2 Pfizer 125 8.3.3 Boehringer Ingelheim 129 8.3.4 Sun Yat-Sen University, China 132 8.3.5 Envivo Pharmaceuticals 133 8.4 Analysis of CNS Desirability of PDE9A Inhibitors 135 8.5 Conclusions 135 References 137 9 Phosphodiesterase 8B 141 Stephen W. Wright 9.1 Introduction 141 9.2 Identification 141 9.3 Properties 142 9.4 Expression and Tissue Distribution 143 9.5 Functions of PDE8B 143 9.5.1 Thyroid 144 9.5.2 Adrenal Gland 144 9.5.3 Pancreatic Islets 144 9.6 Inhibitors and Potential Therapeutic Uses 145 References 150 10 Selective New Small-Molecule Inhibitors of Phosphodiesterase 1 155 John M. Humphrey 10.1 Introduction 155 10.2 PDE1 Enzymology 155 10.3 PDE1 Inhibitors 156 10.3.1 Non-Selective PDE1 Inhibitors 156 10.3.2 Selective PDE1 inhibitors 158 10.4 Conclusion 161 References 163 11 Recent Advances in the Development of PDE7 Inhibitors 165 Nigel A. Swain and Rainer Gewald 11.1 Introduction 165 11.1.1 PDE7: Subtypes and Distribution 165 11.1.2 Rationale for PDE7 as a Therapeutic Target 166 11.2 Historical Development of PDE7 Inhibitors 166 11.2.1 Early Examples of Nonselective and Selective Lead Matter 166 11.2.2 Developing Selective Lead Matter from Nonselective Hits 167 11.2.3 Targeting PDE4/7 Dual Inhibitors 168 11.3 Recent Advances in the Discovery of PDE7 Inhibitors for Peripheral Therapeutic Benefit 169 11.3.1 PDE7 Inhibitors for the Treatment of T Cell-Related Disorders 169 11.3.1.1 Developments in PDE7 Inhibitors for the Treatment of Airway-Related Disorders 170 11.3.1.2 Developments in PDE7 Inhibitors for the Treatment of Nonairway-Related Disorders 171 11.3.1.3 Summary of T-Cell-Related Research 171 11.3.2 PDE7 Inhibitors for the Treatment of Neuropathic Pain 172 11.4 Recent Advances in the Discovery of PDE7 Inhibitors for CNS-Related Disorders 173 11.4.1 Creating PDE7 Inhibitors by Ligand-Based Virtual Screening Methods 173 11.4.2 Repositioning PDE7 Inhibitors Designed for the Treatment of Peripheral Diseases 176 11.5 Recent Advances in the Discovery of Dual PDE7 Inhibitors 178 11.5.1 Dual PDE4/7 Inhibitors 178 11.5.2 Dual PDE7/8 Inhibitors 180 11.6 Identifying Next-Generation PDE7 Inhibitors 181 11.6.1 Emerging Chemotypes as Novel PDE7 Inhibitors 181 11.6.2 Novel Methods to Identify PDE7 Inhibitors 182 11.6.2.1 Computational Methods to Identify New PDE7 Inhibitors 182 11.6.2.2 Fission Yeast-Based HTS to Identify New PDE7 Inhibitors 183 11.7 Summary 184 References 185 12 Inhibitors of Protozoan Phosphodiesterases as Potential Therapeutic Approaches for Tropical Diseases 191 Jennifer L. Woodring and Michael P. Pollastri 12.1 Introduction 191 12.2 Malaria 192 12.2.1 PfPDE Inhibition Studies 193 12.3 Chagas Disease 195 12.4 Leishmaniasis 197 12.5 Human African Trypanosomiasis 200 12.6 Conclusion 205 References 206 Index 211  |
回复此楼» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : Phosphodiesterases_and_Their_Inhibitors.pdf
2016-05-27 20:37:15, 11.71 M
» 猜你喜欢
求调剂
已经有3人回复
-
265求调剂
已经有4人回复
-
085700资源与环境308求调剂
已经有6人回复
-
一志愿吉林大学材料学硕321求调剂
已经有12人回复
-
286分人工智能专业请求调剂愿意跨考！
已经有3人回复
-
329求调剂
已经有5人回复
-
申请回稿延期一个月，编辑同意了。但系统上的时间没变，给编辑又写邮件了，没回复
已经有4人回复
-
材料学硕318求调剂
已经有5人回复
-
一志愿中国海洋大学，生物学，301分，求调剂
已经有6人回复
-
081700化工学硕调剂
已经有3人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 求助书籍一本
已经有1人回复
- Phosphodiesterases and Their Inhibitors
已经有1人回复
简单回复
2016-05-27 23:10
回复
五星好评 顶一下，感谢分享！
2016-05-28 14:22
回复
五星好评 顶一下，感谢分享！
work0374楼
2016-05-28 16:40
回复
五星好评 顶一下，感谢分享！
xwj0075楼
2016-05-29 09:39
回复
五星好评 顶一下，感谢分享！
2016-05-29 10:57
回复
五星好评 顶一下，感谢分享！
2016-05-30 00:02
回复
五星好评 顶一下，感谢分享！
小啊东8楼
2016-05-31 14:44
回复
五星好评 顶一下，感谢分享！
独叶一支枪9楼
2016-06-01 12:44
回复
五星好评 顶一下，感谢分享！
fuhuidong10楼
2016-06-01 21:05
回复
五星好评 顶一下，感谢分享！
lidlbhl-fjnu11楼
2016-06-01 21:21
回复
五星好评 顶一下，感谢分享！
真心真毅12楼
2016-06-01 23:53
回复
五星好评 顶一下，感谢分享！
ha166813楼
2016-06-02 00:46
回复
五星好评 顶一下，感谢分享！
真心真毅14楼
2016-06-02 01:46
回复
顶一下，感谢分享！
Goodman299515楼
2016-06-02 08:57
回复
五星好评 顶一下，感谢分享！
zhzx200916楼
2016-06-03 16:02
回复
五星好评 顶一下，感谢分享！
abc7517楼
2016-08-23 15:16
回复
五星好评 顶一下，感谢分享！
tony_min18楼
2017-01-22 17:32
回复
五星好评 顶一下，感谢分享！
abc7519楼
2017-04-18 22:20
回复
顶一下，感谢分享！
guoxq197220楼
2018-02-11 13:14
回复
五星好评 顶一下，感谢分享！
ronghua432121楼
2018-02-11 22:01
回复
五星好评 顶一下，感谢分享！
tony_min22楼
2018-02-15 21:09
回复
顶一下，感谢分享！
an020823楼
2018-07-21 21:38
回复
五星好评 顶一下，感谢分享！
an020824楼
2019-02-03 16:41
回复
顶一下，感谢分享！
an020825楼
2019-06-06 21:27
回复
顶一下，感谢分享！
an020826楼
2019-06-13 18:53
回复
顶一下，感谢分享！
liumangtu27楼
2019-08-12 08:22
回复
五星好评 顶一下，感谢分享！
